 Clover to procure CpG 1018 adjuvant from Dynavax for use in the commercial production of Clovers COVID-19 vaccine candidate, SCB-2019 CpG 1018Alum Pending conditional regulatory approvals, Clover expects to commence product launch of SCB-2019 CpG 1018Alum by the end of 2021 CHENGDU, China and EMERYVILLE, Calif., June 30, 2021 PRNewswire -- Clover Biopharmaceuticals Clover, a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates to address the worlds most life-threatening diseases and public health threats, and Dynavax Technologies Corporation Dynavax, Nasdaq: DVAX, a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the execution of a commercial supply agreement of Dynavaxs CpG 1018TM advanced adjuvant, for use in Clovers protein-based COVID-19 vaccine candidate, SCB-2019 CpG 1018Alum. 